Follow-On Biologics Study By FTC Aims “To Strike The Right Balance”
This article was originally published in The Pink Sheet Daily
Executive Summary
FTC appears skeptical of generic exclusivity for biologics, but the approval procedure would prove a critical factor.
You may also be interested in...
FTC’s Low Blow On FOBs
FTC concludes that extended brand exclusivity – or any generic exclusivity – is unnecessary for a robust follow-on biologics market.
FTC’s Low Blow On FOBs
FTC concludes that extended brand exclusivity – or any generic exclusivity – is unnecessary for a robust follow-on biologics market.
Teva's Lucky Number Seven: Analysis Supports Shorter Exclusivity For Biologics
Paper by AEI fellow Brill challenges the assumptions in the 16-year estimate from Duke's Grabowski.